These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25664103)

  • 1. Efficacy of short-term cordyceps sinensis for prevention of contrast-induced nephropathy in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.
    Zhao K; Lin Y; Li YJ; Gao S
    Int J Clin Exp Med; 2014; 7(12):5758-64. PubMed ID: 25664103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dongchongxiacao (Cordyceps) therapy on contrast-induced nephropathy in patients with type 2 diabetes and renal insufficiency undergoing coronary angiography.
    Kai Z; Yongjian L; Sheng G; Yu L
    J Tradit Chin Med; 2015 Aug; 35(4):422-7. PubMed ID: 26427112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
    Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
    Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
    J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dongchongxiacao (Cordyceps) in prevention of contrast-induced nephropathy in patients with stable angina pectoris.
    Zhao K; Li Y; Zhang H
    J Tradit Chin Med; 2013 Jun; 33(3):283-6. PubMed ID: 24024319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
    Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention.
    Firouzi A; Kazem Moussavi A; Mohebbi A; Alemzadeh-Ansari MJ; Kiani R; Sanati HR; Mohebbi B; Shakerian F; Zahedmehr A; Ansari-Ramandi MM; Oni Heris S; Ghaleshi B; Ghorbani F
    J Cardiovasc Thorac Res; 2018; 10(3):149-152. PubMed ID: 30386535
    [No Abstract]   [Full Text] [Related]  

  • 11. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome.
    Senoo T; Motohiro M; Kamihata H; Yamamoto S; Isono T; Manabe K; Sakuma T; Yoshida S; Sutani Y; Iwasaka T
    Am J Cardiol; 2010 Mar; 105(5):624-8. PubMed ID: 20185007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Platelet-to-Lymphocyte Ratio and Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.
    Demircelik MB; Kurtul A; Ocek H; Cakmak M; Ureyen C; Eryonucu B
    Cardiorenal Med; 2015 Apr; 5(2):96-104. PubMed ID: 25999958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome.
    Chaudhary AK; Pathak V; Kunal S; Shukla S; Pathak P
    Indian Heart J; 2019; 71(4):303-308. PubMed ID: 31779857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of plasma homocysteinemia on contrast-induced nephropathy after percutaneous coronary intervention in patients with coronary syndrome].
    Yan G; Kong W; Wang D; Qiao Y; Sha X; Cheng T; Zhang H; Hou J; Tang C; Ma G
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Jan; 44(1):32-7. PubMed ID: 26813550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of minimum contrast media volumes during elective percutaneous coronary intervention for prevention of contrast-induced nephropathy in patients with stable coronary artery disease.
    Ebisawa S; Kurita T; Tanaka N; Nasu K; Kimura M; Ito T; Kinoshita Y; Tsuchikane E; Terashima M; Suzuki T
    Cardiovasc Interv Ther; 2016 Jan; 31(1):13-20. PubMed ID: 26001976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of the renal resistive index for contrast-induced nephropathy in patients with acute coronary syndrome.
    Xu ZR; Chen J; Liu YH; Liu Y; Tan N
    BMC Cardiovasc Disord; 2019 Feb; 19(1):36. PubMed ID: 30744553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Neutrophil-to-lymphocyte Ratio with Contrast-induced Nephropathy in Patients with Non-ST-elevation Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention.
    Kurtul A; Yarlioglues M; Duran M; Murat SN
    Heart Lung Circ; 2016 Jul; 25(7):683-90. PubMed ID: 26935164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of hydration and alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients.
    Xu RH; Ma GZ; Cai ZX; Chen P; Zhu ZD; Wang WL
    Exp Ther Med; 2013 Oct; 6(4):863-867. PubMed ID: 24137279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
    Fu N; Yang S; Zhang J; Zhang P; Liang M; Cong H; Lin W; Tian F; Lu C
    Int Urol Nephrol; 2018 Jan; 50(1):105-112. PubMed ID: 29071556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canada Acute Coronary Syndrome Score: A Preprocedural Risk Score for Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention.
    Liu YH; Jiang L; Duan CY; He PC; Liu Y; Tan N; Chen JY
    Angiology; 2017 Oct; 68(9):782-789. PubMed ID: 28135823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.